Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IPHA Innate Pharma > Key Indicators
IPHA Innate Pharma
2.190
-0.100-4.37%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(FY)2021/12/31(Q4)2021/12/31(Q2)2021/06/30
Financial Ratios
Efficiency Ratios TTM
Receivable Turnover(T)
72.55% 4.7617 -73.02% 2.2881 -73.02% 2.2881 -37.28% 2.7596
Fixed Assets Turnover(T)
41.61% 4.4092 -77.23% 1.1076 -77.23% 1.1076 -21.44% 3.1135
Total Asset Rate(T)
36.10% 0.1649 -73.73% 0.0421 -73.73% 0.0421 -12.04% 0.1212
ROIC
64.21% -14.717% -3.53% -32.333% -3.53% -32.333% -112.28% -41.117%
ROE
59.77% -18.237% -16.99% -40.095% -16.99% -40.095% -98.91% -45.334%
ROA
67.71% -8.337% -1.75% -18.371% -1.75% -18.371% -99.66% -25.821%
Efficiency Ratios
ROE 5 Year Average
-- -- -67.64% -27.795% -- -- -- --
ROA 5 Year Average
-- -- -63.35% -11.693% -- -- -- --
Average 5 Years ROIC
-- -- -61.68% -24.947% -- -- -- --
Profitability Ratios TTM
Operating Margin
44.99% -44.710% -1,110.20% -394.938% -1,110.20% -394.938% 14.43% -81.281%
Net Margin
76.28% -50.551% -287.34% -436.078% -287.34% -436.078% -126.98% -213.073%
EBITDA Margin
45.33% -0.3733% -2,681.16% -3.3501% -2,681.16% -3.3501% -27.92% -0.6829%
R & D Expense Ratio
-16.41% 112.590% 276.36% 388.140% 276.36% 388.140% 1,922.60% 134.690%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-51.41% 34.360% 183.13% 132.050% 183.13% 132.050% -27.28% 70.720%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-0.74% 10.765% 15.68% 12.568% 15.68% 12.568% 34.27% 10.845%
Total Assets to Common Equity
20.94% 241.058% 26.32% 248.972% 26.32% 248.972% 24.34% 199.322%
Debt to Asset Ratio
201.77% 37.284% 236.57% 41.187% 236.57% 41.187% 36.43% 12.355%
Current Ratio
-23.25% 2.3354 -54.61% 1.7307 -54.61% 1.7307 53.08% 3.043
Quick Ratio
-26.21% 2.2455 -52.43% 1.7307 -52.43% 1.7307 53.08% 3.043
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -329.78% -46.681% -- -- -- --
Revenue CAGR(5Y)
-- -- -201.68% -26.423% -- -- -- --
Currency Unit
EUREUREUREUR

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herv? Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fourni?, and Fran鏾is Romagn? on September 23, 1999 and is headquartered in Marseille, France.
CEO: Dr. Mondher Mahjoubi, M.D.
Market: NASDAQ
Listing Date: 10/17/2019
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist